Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction
Authors
Keywords
-
Journal
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 326, Issue 19, Pages 1919
Publisher
American Medical Association (AMA)
Online
2021-11-17
DOI
10.1001/jama.2021.18463
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical profile and contemporary management of patients with heart failure with preserved ejection fraction: results from the CHECK-HF registry
- (2021) A. Uijl et al. Netherlands Heart Journal
- Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction
- (2020) Jonathan W. Cunningham et al. JACC-Heart Failure
- Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction
- (2020) Paul W. Armstrong et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction
- (2020) James E. Udelson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists
- (2020) Andrew P. Ambrosy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
- (2020) William T Abraham et al. EUROPEAN HEART JOURNAL
- Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction
- (2019) Sanjiv J. Shah et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- (2019) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
- (2019) Scott D. Solomon et al. CIRCULATION
- Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum
- (2018) Lars H. Lund et al. EUROPEAN JOURNAL OF HEART FAILURE
- Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry
- (2018) Finn Gustafsson et al. EUROPEAN HEART JOURNAL
- Unknown
- (2018) STATISTICS IN MEDICINE
- Heart Failure with Preserved Ejection Fraction
- (2016) Margaret M. Redfield NEW ENGLAND JOURNAL OF MEDICINE
- Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction
- (2015) Scott D. Solomon et al. EUROPEAN HEART JOURNAL
- Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction
- (2015) William T. Abraham et al. JACC-Heart Failure
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial
- (2014) Kathleen Nolte et al. European Journal of Preventive Cardiology
- Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction
- (2013) Frank Edelmann et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction
- (2013) Margaret M. Redfield et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
- (2012) Scott D Solomon et al. LANCET
- Impact of Cardiac Resynchronization Therapy on Exercise Performance, Functional Capacity, and Quality of Life in Systolic Heart Failure With QRS Prolongation: COMPANION Trial Sub-Study
- (2008) Teresa De Marco et al. JOURNAL OF CARDIAC FAILURE
- Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
- (2008) Barry M. Massie et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started